We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Future product development will focus on additional respiratory infections and sexually transmitted diseases, among others, the company said. Read More
Pfizer has completed its acquisition of Australian diagnostic software developer ResApp Health for $115 million, expanding its reach into digital health products. Read More
RIGImmune announced its acquisition of Subintro, a move the company says is focused on development of intranasal delivery of RIGImmune’s stem-loop RNA antivirals and vaccines to treat and prevent respiratory diseases caused by RNA viruses such as COVID-19, influenza, RSV and rhinoviruses. Read More